---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-015834"
form_type: "8-K"
ticker: null
cik: "0000855654"
company_name: "ImmunoGen, Inc."
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T15:41:07.340358+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunoGen appoints Lauren White as SVP and CFO effective Sept. 18, 2023

## Summary
- White previously served as CFO of C4 Therapeutics and VP at Novartis, with over 20 years experience.
- Annual salary of $500,000 with bonus eligibility up to 40% of base salary.
- Granted option for 295,975 shares and 51,625 RSUs under 2019 Inducement Plan.
- Renee Lentini steps down as principal financial officer but remains principal accounting officer.

## SEC filing metadata
- accession: 0001558370-23-015834
- form_type: 8-K
- cik: 0000855654
- company_name: ImmunoGen, Inc.
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/855654/000155837023015834/0001558370-23-015834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/855654/000155837023015834/imgn-20230918x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-015834
- JSON: https://secwatch.observer/filing/0001558370-23-015834.json
- Plain text: https://secwatch.observer/filing/0001558370-23-015834.txt

## Key facts
- Executive change
  Renee Lentini changed role as Vice President, Finance and Chief Accounting Officer at ImmunoGen, Inc..
  - Action: ceased to be principal financial officer
  - Role: Vice President, Finance and Chief Accounting Officer
  source text: Effective September 18, 2023, Renee Lentini, the Company’s Vice President, Finance and Chief Accounting Officer, ceased to be the Company’s principal financial officer but will continue in her role as principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000155837023015834/0001558370-23-015834-index.htm
- Executive change
  Lauren White was appointed as Senior Vice President and Chief Financial Officer at ImmunoGen, Inc..
  - Action: appointed
  - Role: Senior Vice President and Chief Financial Officer
  source text: Effective September 18, 2023, ImmunoGen, Inc. (the “Company”) appointed Lauren White as Senior Vice President and Chief Financial Officer and designated her as the Company’s principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/855654/000155837023015834/0001558370-23-015834-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.